• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Recombinant Vaccines Market Share

    ID: MRFR/Pharma/4672-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Recombinant Vaccines Market Research Report Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) - Global Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Recombinant Vaccines Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Share

    Recombinant Vaccines Market Share Analysis

    Within the broad pharmaceutical and biotechnology sector, the Recombinant Vaccines market employs various strategic methods aimed at gaining competitive edge in addition to responding to changing vaccine development landscapes. A chief tactic is through ongoing research and innovation in recombinant vaccines’ manufacturing. They spend a lot of money on research and development for vaccines made through genetic engineering that can enhance safety, have better efficacy rates, as well as offer more extensive protection against diseases targeted. Consequently, these companies bring advanced solutions into the market to distinguish themselves from competition and occupy a huge share of the prices of this kind of vaccines.

    Recombinant Vaccines sector’s positioning on market share is determined by pricing strategies. Due to their significance in public health, some companies adopt different pricing models for their vaccines. Some firms may choose competitive pricing so that many people can afford their medicines while others might prefer value-based pricing where they sell at higher prices just because recombinant vaccines have distinct advantages over the other types of vaccines that are currently available in the market. This balance between how much it costs and how valuable it is guarantees spread of such innovations across most populations but also demands profits.

    Success within the Recombinant Vaccines market depends heavily on collaborations and partnerships. Partnerships with research institutions, governmental bodies or global organizations assist companies during vaccine development and distribution process thereby enabling them pool resources together with knowledge that relates to complexities involved in doing so. Such collaborative works expedite both scientific investigations as well as regulatory processes besides offering opportunities for global marketing thus strengthening supply chains which makes businesses major players within Recombinant Vaccines industry.

    Influencing any given segment’s market share in Recombinant Vaccines necessitates having proper marketing plus branding strategies implemented diligently by companies operating there. Companies run heavy marketing campaigns geared towards communicating product benefits to clients, creating awareness among healthcare providers and general population about its availability while establishing trust of people towards its safety along with effectiveness. The overall idea is to get involved in education, public relations and global health forums among other things that will create a strong brand presence, thus influencing market share and positioning within the competitive arena.

    For firms aiming at consolidating their market share in the Recombinant Vaccines segment, geographical expansion is an important consideration. Picking locations with high prevalence rates of diseases and adapting strategies that are appropriate to local needs are imperative. When dealing with different parts of the world, businesses must tailor products so as to align them with respective cultural backgrounds or regulatory environments. In this way, it becomes possible for companies to penetrate markets successfully by tailoring their product offerings, distribution channels as well as marketing approaches depending on the distinct cultural settings and regulations existing there.

    Investment in post-market surveillance, pharmacovigilance and public health interventions is also essential in order to keep up as well as expand dominance within Recombinant Vaccines industry. Constant monitoring of vaccine safety plus efficacy alongside effective patient education programs enhance trust from professionals within healthcare industry including common people who use vaccines on patients. Therefore, vendors’ continuous commitment towards safety together with general welfare is what maintains their sales levels ensuring they remain recognized stakeholders within the recombinant vaccines industry.

    Market Summary

    The Global Recombinant Vaccines Market is projected to experience substantial growth from 0.36 USD Billion in 2024 to 1.94 USD Billion by 2035.

    Key Market Trends & Highlights

    Global Recombinant Vaccines Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 16.56% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.94 USD Billion, indicating robust expansion.
    • In 2024, the market is valued at 0.36 USD Billion, highlighting its current size and potential for growth.
    • Growing adoption of recombinant vaccine technology due to increasing awareness of vaccine-preventable diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.36 (USD Billion)
    2035 Market Size 1.94 (USD Billion)
    CAGR (2025-2035) 16.56%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.

    Market Trends

    The ongoing advancements in biotechnology are likely to enhance the efficacy and accessibility of recombinant vaccines, thereby playing a crucial role in global health initiatives.

    World Health Organization (WHO)

    Recombinant Vaccines Market Market Drivers

    Market Growth Projections

    Government Initiatives and Funding

    Government initiatives and funding significantly influence the Global Recombinant Vaccines Market Industry. Many countries are increasing their investments in vaccine research and development to combat infectious diseases. For example, national health agencies are allocating substantial budgets to support the development of recombinant vaccines, which are often seen as a cost-effective solution for public health challenges. These initiatives not only facilitate the advancement of vaccine technology but also encourage collaboration between public and private sectors. As governments recognize the critical role of vaccines in safeguarding public health, the financial backing for recombinant vaccine projects is expected to grow, thereby enhancing the market landscape.

    Rising Demand for Preventive Healthcare

    The Global Recombinant Vaccines Market Industry experiences a notable surge in demand for preventive healthcare solutions. As populations become increasingly aware of the importance of vaccination in preventing infectious diseases, the market is projected to grow from 0.36 USD Billion in 2024 to an estimated 1.94 USD Billion by 2035. This growth indicates a compound annual growth rate (CAGR) of 16.56% from 2025 to 2035. Governments and health organizations are actively promoting vaccination programs, which further drives the demand for recombinant vaccines. This trend reflects a broader shift towards proactive health management, underscoring the significance of vaccines in public health strategies.

    Increasing Incidence of Infectious Diseases

    The rising incidence of infectious diseases is a crucial driver of the Global Recombinant Vaccines Market Industry. With the emergence of new pathogens and the resurgence of previously controlled diseases, the need for effective vaccination strategies has never been more pressing. This trend is particularly evident in regions experiencing outbreaks, where recombinant vaccines can provide rapid responses to emerging health threats. The World Health Organization and other health bodies emphasize the importance of vaccination in controlling disease spread. Consequently, the demand for recombinant vaccines is likely to increase, as they offer a viable solution to mitigate the impact of infectious diseases on global health.

    Technological Advancements in Vaccine Development

    Technological innovations play a pivotal role in shaping the Global Recombinant Vaccines Market Industry. Advances in genetic engineering and biotechnology have streamlined the development of recombinant vaccines, enhancing their efficacy and safety profiles. For instance, the use of recombinant DNA technology allows for the rapid production of vaccines tailored to specific pathogens. This capability not only accelerates the vaccine development process but also ensures a more robust immune response. As research institutions and pharmaceutical companies continue to invest in these technologies, the market is likely to witness an influx of novel vaccines, further propelling its growth and expanding the range of diseases that can be effectively targeted.

    Growing Public Awareness and Acceptance of Vaccines

    Public awareness and acceptance of vaccines are essential factors driving the Global Recombinant Vaccines Market Industry. Educational campaigns and outreach programs have significantly improved understanding of vaccine benefits, leading to higher vaccination rates. This trend is particularly evident in developing countries, where initiatives aimed at increasing vaccine literacy have resulted in greater public trust in vaccination programs. As communities become more informed about the role of vaccines in preventing diseases, the demand for recombinant vaccines is expected to rise. This growing acceptance not only supports public health objectives but also encourages investment in vaccine development, further stimulating market growth.

    Market Segment Insights

    Regional Insights

    Key Companies in the Recombinant Vaccines Market market include

    Industry Developments

    Future Outlook

    Recombinant Vaccines Market Future Outlook

    The Global Recombinant Vaccines Market is projected to grow at a 16.56% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments.

    New opportunities lie in:

    • Develop novel adjuvants to enhance vaccine efficacy and market differentiation.
    • Expand production capabilities in emerging markets to meet rising global demand.
    • Invest in digital health solutions for vaccine distribution and patient engagement.

    By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in global healthcare innovation.

    Market Segmentation

    Market Segmentation

    Recombinant Vaccines Market Segmentation   

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 0.29 (USD Billion)
    Market Size 2024 0.36 (USD Billion)
    Market Size 2032 1.62 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.24 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.
      Key Market Opportunities ·  Raising awareness of healthcare, favorable reimbursement policies ·  Increasing innovations in research and development of drugs, and vaccines ·  Rising average income of individuals
      Key Market Drivers ·  Increasing technical advanced devices ·  Increasing number of regulatory approvals ·  The high prevalence of infectious diseases ·  Growing penetration of key market players

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the growth rate of the global recombinant vaccines market?

    The global recombinant vaccines market is expected to expand at 6.24% CAGR from 2024 to 2032.

    Who are the major players of the global recombinant vaccines market?

    Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.

    What are the restraining factors of the global recombinant vaccines market?

    High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.

    Which region can dominate in the global recombinant vaccines market?

    The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.

    What are major drivers of the global recombinant vaccines market?

    High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.

    1.  Table of Content    
    2.     Report Prologue    
    3.     Market Introduction    
      1.     Definition    
      2.     Scope of the Study    
        1.     Research Objective    
        2.     Assumptions    
        3.     Limitations    
    4.     Research Methodology
      1.     Introduction
      2.     Primary Research    
      3.     Secondary Research    
      4.     Market Size Estimation
    5.     Market Dynamics
      1.     Drivers    
      2.     Restraints
      3.     Opportunities    
      4.     Challenges
      5.     Macroeconomic Indicators
      6.     Technology Trends & Assessment
    6.     Market Factor Analysis
      1.     Porter’s Five Forces Analysis
        1.     Bargaining Power of Suppliers    
        2.     Bargaining Power of Buyers
        3.     Threat of New Entrants    
        4.     Threat of Substitutes    
        5.     Intensity of Rivalry    
      2.     Value Chain Analysis
      3.     Investment Feasibility Analysis    
      4.     Pricing Analysis
    7.     Global Recombinant Vaccines Market, by Route of Administration
    8.      6.1    Introduction
      1. Intramuscular and Subcutaneous Administration
    9. •    Market Estimates & Forecast, 2020–2027    
    10. •    Market Estimates & Forecast, by Region/Country, 2020–2027
    11.       6.3 Oral Administration
    12. •    Market Estimates & Forecast, 2020–2027    
    13. •    Market Estimates & Forecast, by Region/Country, 2020–2027
    14.             6.4 Other Routes of Administration
    15.     Global Recombinant Vaccines Market, by Type
      1.     Introduction
      2.     Subunit recombinant vaccines
    16. •    Market Estimates & Forecast, 2020–2027    
      1.     Attenuated recombinant vaccines
    17. •    Market Estimates & Forecast, 2020–2027    
    18. •    Market Estimates & Forecast, by Region/Country, 2020–2027
    19.             7.4          Vector recombinant vaccines
    20.                                    •    Market Estimates & Forecast, 2020–2027    
    21.                                     •    Market Estimates & Forecast, by Region/Country, 2020–2027
    22.     Global Recombinant Vaccines Market, by Disease
      1.     Introduction
      2.     Pneumococcal Disease
    23. •    Market Estimates & Forecast, 2020–2027    
      1.     Cancer
      2.     Hepatitis B
      3.     Influenza
    24.              8.6       HPV (Human papillomavirus)
    25.        •    Market Estimates & Forecast, 2020–2027    
    26.        •    Market Estimates & Forecast, by Region/Country, 2020–2027
    27.             8.7        DPT
    28.           8.8       Others
    29.        •    Market Estimates & Forecast, 2020–2027    
    30.        •    Market Estimates & Forecast, by Region/Country, 2020–2027
    31.     Global Recombinant Vaccines Market, by End-User
      1.     Introduction
      2.     Hospitals & Clinics
      3.     Pediatrics
      4.        Adults
    32.            9.5          Veterinary
    33.       •    Market Estimates & Forecast, 2020–2027    
    34.                    •    Market Estimates & Forecast, by Region/Country, 2020–2027
    35.                 9.5.1 Poultry
    36.                    9.5.2 Livestock
    37. •    Market Estimates & Forecast, by Region/Country, 2020–2027  
      1. Others
    38. 10    Global Recombinant Vaccines Market, by Region
      1.     Introduction
      2.     Americas
    39. •    Market Estimates & Forecast, by Region, 2020–2027
    40. •    Market Estimates & Forecast, by Type, 2020–2027
    41. •    Market Estimates & Forecast, by  Disease, 2020–2027
    42. •    Market Estimates & Forecast, by End-User, 2020–2027
      1.     North America
    43. •    Market Estimates & Forecast, by Country, 2020–2027
    44. •    Market Estimates & Forecast, by Type, 2020–2027
    45. •    Market Estimates & Forecast, by  Disease, 2020–2027
    46. •    Market Estimates & Forecast, by End-User, 2020–2027
      1.     U.S.
    47. •    Market Estimates & Forecast, by Type, 2020–2027
    48. •    Market Estimates & Forecast, by  Disease, 2020–2027
    49. •    Market Estimates & Forecast, by End-User, 2020–2027
      1.     Canada
    50. •    Market Estimates & Forecast, by Type, 2020–2027
    51. •    Market Estimates & Forecast, by  Disease, 2020–2027
    52. •    Market Estimates & Forecast, by End-User, 2020–2027
      1.     South America
    53. •    Market Estimates & Forecast, by Type, 2020–2027
      1.     Europe
    54. •    Market Estimates & Forecast, by Region, 2020–2027
      1.     Western Europe
    55. •    Market Estimates & Forecast, by Country, 2020–2027
    56. •    Market Estimates & Forecast, by Type, 2020–2027
    57. •    Market Estimates & Forecast, by  Disease, 2020–2027
      1.     Germany
    58. •    Market Estimates & Forecast, by Type, 2020–2027
    59. •    Market Estimates & Forecast, by  Disease, 2020–2027
    60. •    Market Estimates & Forecast, by End-User, 2020–2027
      1.     France
        1.     U.K.
        2.     Eastern Europe
    61. •    Market Estimates & Forecast, by Type, 2020–2027
      1.     Asia Pacific
    62. •    Market Estimates & Forecast, by Country, 2020–2027
      1.     Japan
        1.     China
        2.     India
        3.     Australia
        4.     Republic of Korea
        5.     Rest of Asia Pacific
    63. •    Market Estimates & Forecast, by Disease, 2020–2027
      1.     The Middle East & Africa
    64. •    Market Estimates & Forecast, by Region, 2020–2027
      1.     United Arab Emirates
        1.      Saudi Arabia
        2.     Oman
        3.     Kuwait
        4.     Qatar
        5.     Rest of the Middle East & Africa
    65. 11    Company Landscape    
      1.     Introduction    
      2.     Market Share Analysis    
      3.     Key Development & Strategies    
        1.     Key Developments    
    66. 12    Company Profiles    
      1.      Astellas Pharma Inc
        1.     Company Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     SWOT Analysis    
      2.      CSL Limited 
        1.     Company Overview    
        2.     Route of Administration Overview    
        3.     Financial Overview    
        4.     Key Developments    
        5.     SWOT Analysis    
      3.     Emergent BioSolutions, Inc.
        1.     Company Overview    
        2.     Route of Administration Overview    
        3.     Financial Overview
        4.     Key Development    
        5.     SWOT Analysis    
      4.     GlaxoSmithKline
        1.     Company Overview    
        2.     Route of Administration/Business Segment Overview    
        3.     Financial Overview    
        4.     Key Development    
        5.     SWOT Analysis    
      5.     Johnson & Johnson (U.S.)
        1.     Company Overview    
        2.     Route of Administration Overview    
        3.     Financial overview    
        4.     Key Developments    
      6.     Mitsubishi Tanabe Pharma Corporation 
        1.     Company Overview    
        2.     Route of Administration Overview    
        3.     Financial Overview    
        4.     Key Developments    
      7.     Merck & Co., Inc. 
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      8.     Pfizer, Inc.. 
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      9.     Sanofi Pasteur SA
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      10.     Serum Institute of India Pvt. Ltd
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      11.     Bavarian Nordic
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      12.     Mitsubishi Tanabe Pharma Corporation
        1.     Overview    
        2.     Route of Administration Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis    
      13.     Daiichi Sankyo
    67.             12.13.1    Overview    
      1.     Route of Administration Overview    
        1.     Financials    
        2.     Key Developments    
        3.     SWOT Analysis    
    68. 13    MRFR Conclusion    
      1.     Key Findings    
        1.     From CEO’s View Point    
        2.     Unmet Needs of the Market    
      2.     Key Companies to Watch    
      3.     Prediction of Pharmaceutical Industry
    69. 14    Appendix
    70. List of Tables and Figures
      1. LIST OF TABLES
      2. Table 1         Recombinant Vaccines Industry Synopsis, 2020–2027
      3. Table 2        Global Recombinant Vaccines Market Estimates and Forecast, 2020–2027, (USD Million)
      4. Table 3        Global Recombinant Vaccines Market by Region, 2020–2027, (USD Million)
      5. Table 5        Global Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      6. Table 6            Global Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      7. Table 7     Global Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      8. Table 8        North America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      9. Table 9            North America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      10. Table 10    North America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      11. Table 11    US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      12. Table 12           US Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      13. Table 13    US Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      14. Table 14    Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      15. Table 15    Million)  
      16. Table 16    Canada Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      17. Table 17    Canada Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      18. Table 18    South America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      19. Table 19          South America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      20. Table 20    South America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      21. Table 21    Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      22. Table 22    Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      23. Table 23    Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      24. Table 24    Western Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      25. Table 25    Western Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      26. Table 26    Western Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      27. Table 27    Eastern Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)  
      28. Table 28    Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      29. Table 29    Eastern Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      30. Table 30    Asia Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      31. Table 31    Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)
      32. Table 32    Asia Pacific Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)
      33. Table 33    Middle East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)
      34. Table 34    Middle East & Africa Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)   LIST OF FIGURES
      35. Figure 1    Research Process
      36. Figure 2    Segmentation for Global Recombinant Vaccines Market
      37. Figure 3    Segmentation Market Dynamics for Recombinant Vaccines Market
      38. Figure 4    Global Recombinant Vaccines Market Share, by Type 2020
      39. Figure 5    Global Recombinant Vaccines Market Share, by End-Users, 2020
      40. Figure 6    Global Recombinant Vaccines Market Share, by Region, 2020
      41. Figure 7    North America Recombinant Vaccines Market Share, by Country, 2020
      42. Figure 8    Europe Recombinant Vaccines Market Share, by Country, 2020
      43. Figure 9    Asia Pacific Recombinant Vaccines Market Share, by Country, 2020
      44. Figure 10    Middle East & Africa Recombinant Vaccines Market Share, by Country, 2020
      45. Figure 11    Global Recombinant Vaccines Market: Company Share Analysis, 2020 (%)
      46. Figure 12     Astellas Pharma Inc: Key Financials
      47. Figure 13     Astellas Pharma Inc: Segmental Revenue
      48. Figure 14     Astellas Pharma Inc: Geographical Revenue
      49. Figure 15    Emergent BioSolutions, Inc.. Key Financials
      50. Figure 16    Emergent BioSolutions, Inc.: Segmental Revenue
      51. Figure 17    Emergent BioSolutions, Inc.: Geographical Revenue
      52. Figure 18    Pfizer, Inc.. : Key Financials
      53. Figure 19    Pfizer, Inc.. : Segmental Revenue
      54. Figure 20    Pfizer, Inc.. : Geographical Revenue
      55. Figure 21    GlaxoSmithKline: Key Financials
      56. Figure 22    GlaxoSmithKline: Segmental Revenue
      57. Figure 23    GlaxoSmithKline: Geographical Revenue
      58. Figure 24    Mitsubishi Tanabe Pharma Corporation : Key Financials
      59. Figure 25    Mitsubishi Tanabe Pharma Corporation : Segmental Revenue
      60. Figure 26    Mitsubishi Tanabe Pharma Corporation . Geographical Revenue
      61. Figure 29     Bavarian Nordic. Key Financials
      62. Figure 30    Bavarian Nordic. Segmental Revenue
      63. Figure 31    Bavarian Nordic. Geographical Revenue

    Recombinant Vaccines Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials